Omega-6 fatty acids

Omega-6 Fatty Acids

1. Identity: Chemical Names, Natural Sources, and Common Forms

Chemical Identity and Classification

Omega-6 fatty acids are fatty acids where the term "omega-6" signifies that the first double bond in the carbon backbone of the fatty acid occurs in the omega minus 6 position — that is, the sixth carbon from the methyl end of the fatty acid chain. Both omega-3 and omega-6 essential fatty acids (EFAs) are polyunsaturated fatty acids (PUFA). What distinguishes the two types is the placement of the first double bond relative to the methyl end of the molecule: omega-6 EFAs have their first double bond at the sixth carbon position.

The omega-6 fatty acid family includes linoleic acid (LA, C18:2 n-6), γ-linolenic acid (GLA, 18:3 n-6), dihomo-γ-linolenic acid (DGLA, 20:3 n-6), and arachidonic acid (AA, C20:4 n-6).

Only linoleic acid is considered truly essential, since the body contains enzymes with which it can synthesize all other omega-6 EFAs from linoleic acid. Humans can synthesize longer omega-6 fatty acids from the essential fatty acid linoleic acid through a series of desaturation (addition of a double bond between two carbon atoms) and elongation (addition of two carbon atoms) reactions.

Individual Members

• Linoleic acid (LA, 18:2 n-6): The parent fatty acid of the omega-6 series. The most abundant member of this family in food and in the body. Other members include gamma-linolenic acid and arachidonic acid. Linoleic acid is considered an essential fatty acid since it cannot be synthesized by the body.
• Gamma-linolenic acid (GLA, 18:3 n-6): An 18-carbon polyunsaturated fatty acid found in human milk and several botanical seed oils and typically consumed as part of a dietary supplement.
• Dihomo-gamma-linolenic acid (DGLA, 20:3 n-6): Its position at a pivotal point of metabolic pathways leading to anti-inflammatory derivatives or via arachidonic acid to pro-inflammatory lipid mediators makes this n-6 PUFA an intriguing research subject.
• Arachidonic acid (AA, C20:4 n-6): A physiologically significant n-6 fatty acid and the precursor for prostaglandins and other physiologically active molecules.

Natural Food Sources

Highest amounts of linoleic acid are found in certain vegetable oils such as corn, safflower, grapeseed, and sunflower oil, and in other foods such as nuts and seeds. Arachidonic acid is found in small amounts in meat, fish (especially farmed tilapia), milk products, and egg yolk. Gamma-linolenic acid is not found in significant amounts in common foods but is high in supplements such as borage oil, evening primrose oil, and black currant seed oil.

Regarding GLA content in botanical oils: Seed oils such as borage (Borago officinalis) oil (approximately 18–26 wt-% of GLA), blackcurrant (Ribes nigrum) oil (15–20%), and evening primrose (Oenothera biennis) oil (7–10%), as well as fungal oils (23–26%) are rich sources of GLA.

Supplement Forms and Preparations

Omega-6 fatty acids are available in several supplemental forms. In plants and animal-based food, omega-6 fatty acids are mostly found in the form of triacylglycerols (TAG), phospholipids (PL), diacylglycerols (DAG), and cholesterol esters, but they may also appear as free fatty acids and ethyl esters, with phospholipids being the most bioavailable because of their aliphatic characteristics. When sold as dietary supplements, they are most commonly encountered as soft-gel capsules of borage oil, evening primrose oil, or black currant seed oil — all standardized for their GLA content. Evening primrose oil contains about 74% linoleic acid and 10% gamma-linolenic acid. Borage oil contains about 18% to 26% GLA. Other plant oils also contain GLA: evening primrose contains between 7% and 10%, and black currant oil contains 15% to 20%.

2. Traditional and Historical Use

Evolutionary and Pre-Industrial Diet

During prehistoric evolution, hominins obtained the essential polyunsaturated fatty acids, omega-6 and omega-3, by consuming fruit, vegetables, seeds and nuts, and animal organ meats including marine life. Modern diet has diverted from one very rich with omega-3 PUFA and a well-balanced ratio of omega-6 to omega-3 (1:1), to one rich with saturated fatty acids and omega-6 instead of omega-3.

Scientific Discovery of EFAs

In 1929, Burr and Burr discovered the essential fatty acids omega-6 and omega-3 — a landmark finding that established that certain polyunsaturated fatty acids could not be synthesized by mammals and must be obtained through diet. In the 1950s, Ancel Keys in well-controlled feeding trials showed that polyunsaturated fatty acids had a weaker but opposite effect on the blood cholesterol–raising effects compared with saturated fatty acids.

Traditional Therapeutic Use of GLA-Rich Oils

Evening primrose is a plant native to North and South America that also grows throughout Europe and parts of Asia. It has yellow flowers that open at sunset. The oil from evening primrose seeds contains omega-6 fatty acids, including gamma-linolenic acid. Native Americans applied juices from the plant's stem and leaves to the skin to treat skin inflammation, bruises, and minor wounds, and they used the leaves orally for gastrointestinal disorders and sore throats.

20th-Century Dietary Shift

From the advent of the industrial revolution until the twentieth century, the yield and stability and the quality and form of fatty acid products were radically improved by the introduction of new techniques for fat extraction, refrigeration, preservatives, antioxidants, and by the hydrogenation of unsaturated fatty acids. These aspects had a great impact on the evolution of the fats industry and market, and consequently on human usage. Saturated fats became cheaper and easily accessible for the population in the form of butter, shortenings, and margarine, radically changing the western diet.

The estimated per capita consumption of soybean oil increased more than 1,000-fold from 1909 to 1999. The availability of linoleic acid (LA) increased from 2.79% to 7.21% of energy over that same period. The ratio of LA to alpha-linolenic acid (ALA) increased from 6.4 in 1909 to 10.0 in 1999.

3. Key Constituents, Active Compounds, and Mechanisms of Action

Metabolic Pathway

Humans synthesize longer omega-6 fatty acids from linoleic acid through a series of desaturation and elongation reactions. Linoleic acid and alpha-linolenic acid compete for the same elongase and desaturase enzymes in the synthesis of longer polyunsaturated fatty acids such as arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid.

When consumed in food, omega-6 fatty acids are mostly assimilated into triacylglycerols (TAG) and undergo digestion in the small intestine. The destruction of the TAG structure and liberation of fatty acids allows absorption and transport in the bloodstream to tissues where they are incorporated into cell structure. The fatty acids can take three different metabolic pathways: (a) esterification into cellular lipids as phospholipids, TAG, or cholesterol esters; (b) beta-oxidation to provide energy for ATP formation; (c) elongation and desaturation through enzymatic reactions to create long-chain PUFAs.

Eicosanoid Production from Arachidonic Acid

Both arachidonic acid and gamma-linolenic acid can be converted to prostaglandins and related substances that affect inflammation, blood clotting, smooth muscle tone, and many other body activities. Cells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid. Eicosanoids produced from arachidonic acid have roles in inflammation.

Omega-6 fatty acids synthesize eicosanoids via cyclooxygenase (COX) and lipoxygenase (LOX) pathways. These eicosanoids include prostaglandins, thromboxanes, and leukotrienes of the 2-series (from AA) and the 4-series (from AA via lipoxygenase), which are generally pro-inflammatory in character at physiological concentrations.

The Anti-Inflammatory Paradox of GLA and DGLA

Although GLA is an n-6 fatty acid — a type generally considered pro-inflammatory — it has anti-inflammatory properties. This is because: GLA is further metabolized to dihomo-gamma-linolenic acid (DGLA), which undergoes oxidative metabolism by cyclooxygenases and lipoxygenases to produce anti-inflammatory eicosanoids (prostaglandins of series 1 and leukotrienes of series 3).

DGLA is the precursor of the prostaglandin PGH1, which in turn forms PGE1 and the thromboxane TXA1. Both PGE1 and TXA1 are anti-inflammatory; thromboxane TXA1, unlike its series-2 variant, induces vasodilation and inhibits platelet aggregation, consequently modulating (reducing) the pro-inflammatory properties of thromboxane TXA2. Unlike arachidonic acid and EPA, DGLA cannot yield leukotrienes, but it can inhibit the formation of pro-inflammatory leukotrienes from arachidonic acid.

The balance of arachidonic acid to DGLA is probably a critical factor affecting inflammatory processes in the body. Critical metabolic and genetic factors affect the conversion of GLA to DGLA and arachidonic acid, which consequently affects the balance of DGLA- and AA-derived metabolites.

Cell Membrane Structure and Gene Regulation

Omega-6 fatty acids contribute to the structure and function of cell membranes and play a part in the regulation of gene activity inside the cell. The PUFA composition of cell membranes is, to a great extent, dependent on dietary intake. Polyunsaturated fatty acids (omega-6 and omega-3) play an important role in the proper anatomo-functional development of the brain. They are involved in the maturation and functioning of neurons, fluidity of the plasma membrane, and gene expression, and are critical elements for cell transduction and learning processes.

Arachidonic acid is especially abundant in the brain and may be important for normal brain development of the fetus and infant.

Several large studies report that higher blood LA levels correlate with reduced risks of coronary heart disease, stroke, and type 2 diabetes. Potential mechanisms include activation of peroxisome proliferator-activated receptors and modulation of oxylipins involved in glucose and lipid metabolism.

The LA-to-Inflammation Controversy

It has been speculated that a high intake of omega-6 polyunsaturated fatty acids may increase the risk of several chronic diseases by promoting low-grade inflammation. The reasoning behind this speculation is that in the human body, linoleic acid is converted into arachidonic acid, which in turn is converted into various inflammation-promoting compounds. However, more recent clinical evidence has substantially challenged this view. Clinical trials have shown that even a very high intake of linoleic acid does not increase inflammatory responses, nor has a significant impact on arachidonic acid levels. In the human body, linoleic acid is converted into various compounds that alleviate inflammation. It is worth noting that arachidonic acid too is converted into inflammation-alleviating compounds, and not just into inflammation-promoting ones.

It is now known that the earlier view of n-6 PUFAs and their derivatives being generally pro-inflammatory and, thus, harmful was an oversimplification. In fact, arachidonic acid and linoleic acid have also been linked to reduced inflammation.

4. Scientific Evidence by Area of Use

4.1 Cardiovascular Disease

The American Heart Association suggests that consuming omega-6 fatty acids (5–10% of total energy) can prevent cardiovascular disease by improving lipoprotein profiles.

Prospective cohort evidence: A pooled individual-level analysis found that higher levels of linoleic acid were associated with lower risks of total cardiovascular disease, ischemic stroke, and cardiovascular mortality, while arachidonic acid was not associated with cardiovascular risk. These findings support potential benefits of the main dietary omega-6 fatty acid, linoleic acid, for cardiovascular disease prevention, and do not support any theorized cardiovascular harms of omega-6 fatty acids.

Meta-analytic evidence: A meta-analysis of 25 case-control studies found a negative correlation between levels of linoleic acid in blood and tissues and coronary heart disease risk. Arachidonic acid was not significantly linked to coronary heart disease risk, though lower levels of AA in adipose tissue were tied to increased coronary heart disease event risk in longitudinal studies. A different meta-analysis covering 13 cohort studies involving 30,602 subjects (with 12,479 coronary heart disease events, including 5,882 fatalities) highlighted the protective effects of increased LA intake against coronary heart disease, indicating that substituting saturated fats with LA could lower coronary heart disease event and death risks by 9 and 13%, respectively.

Umbrella review (2025): An analysis of 150 publications revealed that higher dietary intake and circulating levels of omega-6 were associated with lower risks of cardiovascular diseases, cancer incidence, and all-cause mortality in the general population, particularly for coronary heart disease and stroke.

Limitations and caveats: Inconsistencies in the evidence may stem from factors such as the lack of differentiation between fatty acid types, imprecise intake measurement, and insufficient consideration of dietary background and disease severity — factors contributing to heterogeneity and reducing the certainty of findings. Overall, data from clinical studies and meta-analyses suggest an association between high dietary intakes or tissue levels of n-6 PUFA, and specifically LA, and the improvement of cardiovascular risk (mainly of the plasma lipid profile), as well as long-term glycaemic control and insulin resistance.

4.2 Type 2 Diabetes and Metabolic Syndrome

Large pooled cohort analysis: A pooled analysis included 39,740 adults, aged 49–76 years, who did not have type 2 diabetes at baseline. During a follow-up of 366,073 person-years, 4,347 cases of incident type 2 diabetes were identified. In multivariable-adjusted pooled analyses, higher proportions of linoleic acid biomarkers as percentages of total fatty acid were associated with a lower risk of type 2 diabetes (risk ratio per interquintile range 0.65, 95% CI 0.60–0.72, p<0.0001).

Levels of arachidonic acid biomarker were not significantly associated with type 2 diabetes risk overall. Findings suggest that linoleic acid has long-term benefits for the prevention of type 2 diabetes and that arachidonic acid is not harmful.

Consuming omega-6 fatty acids has also been associated with delayed onset of chronic renal disease in clinical evidence reviewed over a five-year period. Overall, the ideal LA intake level remains uncertain, but current intakes around 5–10% of energy appear beneficial. In other areas like cancer, asthma, and sleep, the evidence is still inconclusive on LA's effects.

4.3 Inflammation — Linoleic Acid and Systemic Markers

C-reactive protein (CRP) levels were measured from 1,287 healthy, 42–60 year-old men at the onset of the Kuopio Ischaemic Heart Disease Risk Factor Study in 1984–1989. The study found that a low serum linoleic acid level was associated with higher serum CRP levels. When participants were divided into four groups based on serum linoleic acid levels, the probability for an elevated CRP was 53% lower in the highest quarter compared to the lowest. Other serum omega-6 fatty acids such as arachidonic acid, gamma-linolenic acid, or dihomo-γ-linolenic acid were not associated with CRP levels.

Some clinical studies indicated that dietary arachidonic acid was not related to an increase of pro-inflammatory cytokines. In summary, there was insufficient evidence to conclude that dietary omega-6 fatty acids have a detrimental effect on inflammatory cytokines in clinical studies.

4.4 Rheumatoid Arthritis (GLA Supplementation)

Clinical studies using GLA (evening primrose oil, borage seed oil, blackcurrant seed oil) suggest a potential relief of pain, morning stiffness, and joint tenderness in rheumatoid arthritis sufferers. Benefits appeared to be increased when dosages were greater than 1.4 g/day of GLA and administered for at least 6 months.

Many of the same issues driving conflicting findings apply to rheumatoid arthritis research as well. Rheumatoid arthritis studies have varied tremendously in length, with some showing the greatest improvements not appearing until one or two years of consistent GLA supplementation, suggesting shorter trials may not adequately capture the full range of effects. Studies likewise show that DGLA and its metabolites are key for reducing rheumatoid arthritis symptoms, partly by DGLA suppressing T cell activation that contributes to joint inflammation, so people with impaired conversion of GLA into DGLA may be less responsive to supplementation.

In vitro and in vivo animal experiments have demonstrated potentially beneficial effects of dietary GLA, the DGLA precursor, on inflammatory conditions such as rheumatoid arthritis and atopic eczema, but clinical data are less convincing. The overall quality of evidence for GLA in rheumatoid arthritis is therefore characterized as preliminary and inconsistent.

4.5 Atopic Dermatitis and Skin Health

Evening primrose oil dietary supplements are promoted for atopic dermatitis (a type of eczema), rheumatoid arthritis, premenstrual syndrome, breast pain, menopause symptoms, and other conditions.

While there have been numerous in vitro and in vivo animal models illustrating that GLA-supplemented diets attenuate inflammatory responses, clinical studies utilizing GLA or GLA in combination with omega-3 PUFAs have been much less conclusive.

A 2025 systematic review of inflammatory skin diseases found: Of 359 records, 57 studies were included (26 psoriasis, 24 atopic dermatitis, 7 acne). Preclinical data consistently demonstrated that specialized pro-resolving mediators modulate key inflammatory pathways, support epithelial repair, and help restore immune balance. Human studies revealed altered cutaneous and systemic lipid mediator profiles — characterized by reduced omega-3–derived specialized pro-resolving mediators and predominance of omega-6-driven inflammatory mediators — suggesting impaired resolution mechanisms across these disorders. The body of evidence is limited by scarce human data, small sample sizes, heterogeneous interventions and variable methods. Many studies rely on subjective or non-standardized clinical outcomes, and the predominance of experimental models further limits the translational relevance of current findings.

4.6 Cancer

In cohort studies, omega-6 fatty acids were associated with prevention of the onset of digestive and lung cancer. However, the evidence is not uniformly favorable.

In animal and laboratory models examining skin cancer: Increasing levels of dietary omega-6 FA increase ultraviolet radiation carcinogenic expression, with respect to a shorter tumor latent period and increased tumor multiplicity. Eicosanoids expressed extensively in the body as a result of the pro-inflammatory response can enhance tumor cell proliferation and growth.

The umbrella meta-analysis of 150 cohorts noted associations between higher circulating omega-6 and lower cancer incidence, but underscored that there may be a threshold of omega-6 intake beyond which risk changes, and clinical trials exploring the effects of replacing other dietary components with omega-6 fatty acids are still needed. Evidence in this domain is considered preliminary and context-dependent, requiring differentiation between specific fatty acid subtypes and dietary patterns.

4.7 Neurodevelopment and Brain Health

Arachidonic acid is especially abundant in the brain and may be important for normal brain development of the fetus and infant. Omega-6 fatty acids are involved in the maturation and functioning of neurons, fluidity of the plasma membrane, and gene expression, and are critical elements for cell transduction and learning processes.

Animal research has raised concerns about the ratio of omega-6 to omega-3 in brain development. A contemporary diet high in 18:2omega-6 compromises DHA accretion and leads to increased 22:4omega-6 and 22:5omega-6 in the brain; an evolutionary diet low in 18:2omega-6 supports high brain DHA. However, these findings derive from animal models and their direct applicability to human nutritional recommendations remains to be established through clinical trials.

4.8 Glaucoma and Muscle Recovery

Consuming omega-6 fatty acids has been reported in the reviewed clinical literature to have positive effects on muscle recovery and glaucoma, though this evidence was drawn from a limited number of studies identified in a five-year clinical literature review and should be considered preliminary.

5. Body Systems Associated with Omega-6 Fatty Acids

• Cardiovascular system: Omega-6 fatty acids improve blood lipoprotein profiles. Higher linoleic acid levels are associated with reduced coronary heart disease risk and cardiovascular mortality in multiple large cohort analyses.
• Immune and inflammatory system: The PUFAs of omega-3 and omega-6 series play a significant role in health and disease by generating potent modulatory molecules for inflammatory responses, including eicosanoids (prostaglandins and leukotrienes), and cytokines (interleukins), and by affecting gene expression of various bioactive molecules.
• Endocrine and metabolic system: Consuming omega-6 fatty acids is associated with delayed onset of diabetes mellitus and chronic renal disease.
• Nervous system: Arachidonic acid is especially abundant in the brain and may be important for normal brain development of the fetus and infant.
• Skin and connective tissue: GLA and its metabolites affect the expression of various genes, regulating gene products including matrix proteins, which play a significant role in immune functions and also in cell death (apoptosis).
• Reproductive system: Evening primrose oil (GLA) is used for premenstrual syndrome, breast pain, and menopause symptoms.
• Cell membranes broadly: The omega-6 and omega-3 classes of PUFA should be distinguished because they are metabolically and functionally distinct and have opposing physiological functions; their balance is important for homeostasis and normal development.

6. Dosage Forms and Dosages Reported in Studies

Dietary Reference Values for Linoleic Acid

The Adequate Intake of linoleic acid recommended for adults by the Institute of Medicine is 11 to 17 grams per day depending on age and gender, which is equivalent to approximately 5 to 6% of total daily calories. The American Heart Association suggests that consuming omega-6 fatty acids at 5–10% of total energy can prevent cardiovascular disease by improving lipoprotein profiles.

Although a recommended dietary allowance for essential fatty acids does not exist, an adequate intake (AI) has been estimated for omega-6 and omega-3 essential fatty acids by an international scientific working group.

GLA Supplementation Dosages in Clinical Studies

Clinical studies using GLA (evening primrose oil, borage seed oil, blackcurrant seed oil) in rheumatoid arthritis suggest benefits appeared to be increased when dosages were greater than 1.4 g/day of GLA and administered for at least 6 months.

Depending on the use, studies have used daily doses of seed oils that provide from as little as 15 mg to as much as 2,000 mg of GLA. Only a part of the seed oil is GLA, so the amount of oil needed could be double or even ten times higher than the dose of GLA itself.

A group of elderly Japanese subjects provided arachidonic acid–enriched oil (240 or 720 mg/day) for 4 weeks did not show a change in inflammatory markers (C-reactive protein, IL-6, and TNF-α) despite an increasing AA concentration.

Current Western Dietary Intake Context

Omega-6 polyunsaturated fatty acids represent almost 15% of the total energy intake in Western countries. Because of the increased use of vegetable oil in the U.S., most American diets are closer to an omega-6 to omega-3 ratio of 1:20 to 1:30 — far above the 1:1 to 1:4 range considered more optimal based on evolutionary dietary data.

7. Safety Considerations and Interactions

General Tolerability

Typical Western diets are abundant in omega-6 fatty acids, so deficiencies usually occur only in special situations, such as starvation and diseases that affect fat absorption. GLA is said to be relatively safe; however, there are concerns that borage oil may be toxic. Evening primrose oil appears to be a safer source of GLA than borage oil.

Gastrointestinal Effects

One of the most commonly reported side effects of GLA supplements is gastrointestinal distress, which can include symptoms such as stomach pain, bloating, nausea, and diarrhea. These issues are generally mild and can often be alleviated by taking the supplement with food or reducing the dosage.

Seizure Risk

Both borage oil and evening primrose oil may lower the seizure threshold. This is a clinically important consideration for individuals with epilepsy or those taking medications that lower the seizure threshold.

Drug Interactions

Cytochrome P450 3A4 is an enzyme that helps the body break down certain medicines. The GLA in evening primrose oil likely interacts with this enzyme. Evening primrose oil can raise or lower some medication levels.

Anticoagulant Effects

Evening primrose oil is rich in omega-6 fatty acids and may act like estrogen. The oil may thin the blood, increase seizure risk, or raise blood pressure.

Allergy

In some cases, individuals may experience an allergic reaction to GLA, particularly if they have a known allergy to the source plant, such as evening primrose, borage, or blackcurrant. Symptoms of an allergic reaction can include rash, itching, swelling, dizziness, and difficulty breathing.

Pregnancy

Women who are pregnant should not use borage oil. Evening primrose oil has been used orally or vaginally to attempt to get labor started at the end of pregnancy, though regulatory bodies have not approved this use due to insufficient controlled clinical evidence.

Omega-6 to Omega-3 Balance Considerations

Linoleic acid and alpha-linolenic acid compete for the same elongase and desaturase enzymes in the synthesis of longer polyunsaturated fatty acids. These two classes of PUFA are metabolically and functionally distinct and have opposing physiological functions; their balance is important for homeostasis and normal development. A balanced omega-6/omega-3 ratio in the diet is essential for normal growth and development and should lead to decreases in cardiovascular disease and other chronic diseases, such as diabetes, hypertension, arthritis, and other autoimmune diseases, and improve mental health. High omega-6 intakes relative to omega-3 intakes may therefore compromise the conversion efficiency of omega-3 precursors to their long-chain bioactive derivatives.

References

• Recent insights into dietary ω-6 fatty acid health effects — PMC, NIH (2022)
• Essential Fatty Acids — Linus Pauling Institute, Oregon State University (2026)
• Omega-3 Versus Omega-6 Polyunsaturated Fatty Acids in Inflammatory Skin Diseases — PMC (2020)
• The Role of Omega-3 and Omega-6 PUFA Supplementation in Human Health — PMC (2025)
• Changes in Consumption of Omega-3 and Omega-6 Fatty Acids in the United States During the 20th Century — PMC / American Journal of Clinical Nutrition (2011)
• A Brief Journey into the History of and Future Sources and Uses of Fatty Acids — Frontiers in Nutrition (2021)
• The Essential Fatty Acids Omega-6 and Omega-3: From Their Discovery to Their Use in Therapy — PubMed (2008)
• Dietary and Circulating Omega-6 Fatty Acids and Their Impact on Cardiovascular Disease, Cancer, and Mortality: Meta-Analysis of 150 Cohorts — PMC (2025)
• Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality — Circulation (2019)
• Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease: Pooled Analysis of 30 Cohort Studies — PMC (2019)
• Omega-6 Fatty Acids and the Risk of Cardiovascular Disease: Systematic Review, Meta-Analysis, and Mendelian Randomization — PMC (2022)
• Omega-6 Fatty Acid Biomarkers and Incident Type 2 Diabetes: Pooled Analysis of 39,740 Adults — PubMed / Lancet Diabetes Endocrinol (2017)
• Omega-6 Fatty Acids: Helpful, Harmless or Harmful? — PubMed (2025)
• Gamma-Linolenic Acid, Dihomo-Gamma Linolenic, Eicosanoids and Inflammatory Processes — ScienceDirect (2016)
• Dihomo-γ-Linolenic Acid (20:3n-6): Metabolism, Derivatives, and Potential Significance in Chronic Inflammation — PMC (2023)
• Omega-3 Fatty Acids and Inflammatory Processes — PMC (2012)
• Omega-6 Fatty Acids Do Not Promote Low-Grade Inflammation — ScienceDaily / University of Eastern Finland (2017)
• The Relationship of Dietary Omega-3 and Omega-6 Intake and Likelihood of Type 2 Diabetes — PMC (2024)
• Specialized Pro-Resolving Lipid Mediators and Dietary Omega-3/6 Fatty Acids in Inflammatory Skin Diseases: Systematic Review — PMC (2025)
• Evening Primrose Oil: Usefulness and Safety — NIH National Center for Complementary and Integrative Health (NCCIH)
• Omega-3 Fatty Acids — NIH Office of Dietary Supplements (2026)
• Borage Oil — University of Rochester Medical Center Encyclopedia
• Effect of Dietary Linoleic Acid on Markers of Inflammation in Healthy Persons: Systematic Review of RCTs — PubMed (2012)
• Incorporation of n-3 PUFA and γ-Linolenic Acid in Blood Lipids and Influence on Disease Activity in Patients With Chronic Inflammatory Arthritis — PMC (2011)
• High Dietary Omega-6 Fatty Acids Contribute to Reduced DHA in the Developing Brain — PubMed (2008)
• Dihomo-γ-Linolenic Acid (20:3n-6): Metabolism, Derivatives, and Significance in Chronic Inflammation — MDPI International Journal of Molecular Sciences (2023)